Two New Manufacturer Notices to 340B Entities on HRSA Website

The generic drug manufacturer recently required to repay covered entities for charging above the ceiling price following an audit has posted a notice on the U.S. Health Services and Resources Administration (HRSA) website about recalculation of ceiling prices and “potential

Read More »

Sanofi Lifts 340B Contract Pharmacy Requirements for Some Providers But Many Are Still Affected

Health centers and four types of hospitals still have to upload their 340B contract pharmacy claims data to a Sanofi vendor to keep getting 340B discounts on Sanofi products. | Source: Shutterstock

Drug manufacturer Sanofi has exempted 11 of the 16 types of health care providers eligible to participate in the 340B program from its conditions on 340B pricing for its products dispensed by contract pharmacies. However, consolidated health center programs (CH),

Read More »

AmeriSourceBergen Has Resumed Distributing 340B-Priced Bausch Health Drugs

340B pricing on Bausch Health products is being restored to AmeriSourceBergen's ordering platforms, 340B Report has learned. | Source: Shutterstock

Drug manufacturer Bausch Health and distributor AmeriSourceBergen Corp. (ABC) apparently have settled their differences and 340B pricing on Bausch Health products is being restored to ABC’s ordering platforms, 340B Report has learned.

Bausch Health blindsided 340B covered entities on

Read More »

Generic Liquid Drug Manufacturer Providing Refunds for 340B Overcharges

The U.S. Health Resources and Services Administration (HRSA) is requiring Pharmaceutical Associates, Inc. (PAI), a South Carolina-based generic liquid drug manufacturer, to repay 340B covered entities for charges on its products above the 340B ceiling price discovered during a fiscal

Read More »

Drug Company Eton Posts 340B Limited Distribution Notice

Illinois-based Eton Pharmaceuticals is making its Alkindi Sprinkle hydrocortisone product available through a sole specialty distributor “to ensure that patients…receive appropriate drug and clinical counseling and to support therapeutic adherence,” the company informed 340B covered entities in a Jan. 12

Read More »

Gilead Adjusts Planned Change in its Patient Assistance After HIV Community Pushes Back

NASTAD and others in the HIV community said they raised their concerns with Gilead about its planned change to its patient assistance program, and the company appears to have listened. | Source: Shutterstock

Drug manufacturer Gilead has altered a planned change to its patient assistance program (PAP) for uninsured people living with HIV that would have been unworkable for some vulnerable patients, HIV/AIDS caregivers and activists say. The change also would have deprived

Read More »

HHS Asks Court to Toss Out Hospitals’ 340B Contract Pharmacy Lawsuit

The lawsuit against HHS by 340B hospitals is just one of several underway over drug manufacturers’ denials of 340B pricing on drugs dispensed by contract pharmacies. | Source: Shutterstock

Outgoing U.S. Health and Human Services (HHS) Secretary Alex Azar last week asked a federal district judge to dismiss a lawsuit against him and his department by 340B hospitals over HHS’s enforcement of its 340B contract pharmacy requirements for drug

Read More »

Senate Finance Report Might Shed Light on Insulin Manufacturers’ 340B Contract Pharmacy Actions

HHS has for the second time delayed the effective date of a Trump administration rule to require health centers to provide insulin and injectable epinephrine to low-income patients at the price the centers pay for those drugs under the 340B program. The new date is July 20. | Shutterstock

U.S. insulin manufacturer and pharmacy benefit manager (PBM) business practices “have created a vicious cycle of price increases that have sent costs for patients and taxpayers through the roof,” U.S. Senate Finance Committee leaders Chuck Grassley (R-Iowa) and Ron Wyden

Read More »

340B Stakeholders Reconsider Campaign Contributions in Wake of Capitol Riot

Businesses and groups involved in 340B are reconsidering their political donations following a pro-Trump mob's assault on the U.S. Capitol. | Source: Shutterstock

National health care organizations and businesses with major stakes in the 340B program have suspended political contributions following a pro-Trump mob’s Jan. 6 violent attack on Congress to stop it from counting and certifying the Electoral College’s votes for president.

Read More »

Health Centers File 340B Dispute Resolution Petitions Against Drug Manufacturers

The National Association of Community Health Centers (NACHC) last night on its members’ behalf asked a new federal 340B program administrative dispute resolution (ADR) panel to order drug manufacturers Eli Lilly and Co., Sanofi, and AstraZeneca to lift all “qualifications,

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live